<table>
<thead>
<tr>
<th>BREAST</th>
<th>Protocol: Alliance A221102 - Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias</th>
<th>Click for more information: <a href="https://www.clinicaltrials.gov/ct2/show/NCT01573442?term=a221102&amp;rank=1">https://www.clinicaltrials.gov/ct2/show/NCT01573442?term=a221102&amp;rank=1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>BREAST</td>
<td>Protocol: Alliance A011203 - A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer</td>
<td>Click for more information: <a href="https://www.clinicaltrials.gov/ct2/show/NCT02311933">https://www.clinicaltrials.gov/ct2/show/NCT02311933</a></td>
</tr>
<tr>
<td>BREAST</td>
<td>Protocol: NSABP B-55 - Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy</td>
<td>Click for more information: <a href="https://www.clinicaltrials.gov/ct2/show/NCT02032823?term=nsabp+b55&amp;rank=1">https://www.clinicaltrials.gov/ct2/show/NCT02032823?term=nsabp+b55&amp;rank=1</a></td>
</tr>
<tr>
<td>BREAST</td>
<td>Protocol: GO29058 SANDPIPER - A Phase III, Double-Blind, Placebo Controlled, Randomized Study of Taselisib Plus Fulvestrant versus Placebo Plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy</td>
<td>Click for more information: <a href="https://clinicaltrials.gov/ct2/show/NCT02340221?term=sandpiper&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02340221?term=sandpiper&amp;rank=1</a></td>
</tr>
</tbody>
</table>
**BREAST**
Adjuvant, Node + or High-Risk Node −, TNBC  
**Location:** Network  
**NSH #:** C-239  
**Status:** OPEN TO ACCRUAL  
**Protocol:** *NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer*  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02488967](https://clinicaltrials.gov/ct2/show/NCT02488967)

**BREAST**  
1\(^{st}\) line Metastatic TNBC Post Adjuvant Therapy  
**Location:** Network  
**NSH #:** C-247  
**Status:** OPEN TO ACCRUAL  
**Protocol:** *DOMPE REP0114 - A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)*  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02370238?term=dompe+rep0114&rank=1](https://clinicaltrials.gov/ct2/show/NCT02370238?term=dompe+rep0114&rank=1)

**GLIOBLASTOMA**  
Adjuvant  
**Location:** Network (Imaging @ NSH ONLY)  
**NSH #:** C-204  
**Status:** OPEN TO ACCRUAL  
**Protocol:** *Alliance A071102 - A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation*  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02152982?term=a071102&rank=1](https://clinicaltrials.gov/ct2/show/NCT02152982?term=a071102&rank=1)

**HEMATOLOGY**  
Observational Bio-specimen Collection  
**Location:** Network  
**NSH #:** NSH1145  
**Status:** OPEN TO ACCRUAL  
**Protocol:** *Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome*  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02269592?term=NCT02269592&rank=1](https://clinicaltrials.gov/ct2/show/NCT02269592?term=NCT02269592&rank=1)

**LEUKEMIA**  
Relapsed or Refractory CLL with prior BTK or PI3K  
**Location:** GCS Research Offices  
**NSH #:** C-124  
**Status:** OPEN TO ACCRUAL  
**Protocol:** *Gilead GS-US-339-0102 - A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies*  
**Click for more information:** [https://www.clinicaltrials.gov/ct2/show/study/NCT01799889?term=gs-us-339-0102&rank=1](https://www.clinicaltrials.gov/ct2/show/study/NCT01799889?term=gs-us-339-0102&rank=1)

**LUNG**  
Unresectable Stage IIIA or IIIB Non-Squamous NSCLC  
**Location:** Network (RT must be @ NSH ONLY)  
**NSH #:** NSH1121  
**Status:** OPEN TO ACCRUAL  
**Protocol:** *RTOG1306 A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)*  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT01822496?term=rtog1306&rank=1](https://clinicaltrials.gov/ct2/show/NCT01822496?term=rtog1306&rank=1)

For further information and/or to refer a patient, please e-mail: [Research@gacancer.com](mailto:Research@gacancer.com)  
List Updated: 5/13/2016
### LUNG

#### 2<sup>nd</sup> line + Metastatic Squamous Cell Carcinoma

| Sub-study B | Target P13k (GDC-0032) |
| Sub-study C | Target CDK4/6 (Palbociclib) |
| Sub-study D | Target FGFR (AZD4547) |
| Sub-study I | Target (Nivolumab + Ipilimumab or Nivolumab) |

**Location:** Network  
**NSH #:** C-163  
**Status:** OPEN TO ACCRUAL  

**Protocol:** SWOG S1400 Lung-MAP - A Bio-marker Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer  
**Click for more information:** [https://www.clinicaltrials.gov/ct2/show/NCT02154490](https://www.clinicaltrials.gov/ct2/show/NCT02154490)

All eligible patients will be enrolled to protocol S1400 for biomarker profiling per Foundation Medicine. Based on those results, patients meeting detailed eligibility criteria will be assigned to one of the Sub-Studies.

### LUNG

#### Adjuvant ALK + or EGFR +

*All eligible patients will be enrolled to protocol A151216 in order to have tumor genotyping performed per central lab.*

**If patient is EGFR +, they may be enrolled to protocol A081105.**

**If patient is ALK +, they may be enrolled to protocol E4512.**

**Location:** Network  
**NSH #:** C-190, C-191, C-192  
**Status:** OPEN TO ACCRUAL  

**Protocol:** Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02194738?term=alchemist&rank=2](https://clinicaltrials.gov/ct2/show/NCT02194738?term=alchemist&rank=2)

**Protocol:** Alliance A081105 - Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02193282?term=alchemist&rank=3](https://clinicaltrials.gov/ct2/show/NCT02193282?term=alchemist&rank=3)

**Protocol:** Alliance E4512 - A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02201992?term=alchemist&rank=4](https://clinicaltrials.gov/ct2/show/NCT02201992?term=alchemist&rank=4)

### LUNG

#### 1<sup>st</sup> line Extensive Stage Small Cell

**Location:** Network  
**NSH #:** C-198  
**Status:** OPEN TO ACCRUAL  

**Protocol:** Oncomed 59R5-003 PINNACLE - A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT01859741?term=Pinnacle&rank=7](https://clinicaltrials.gov/ct2/show/NCT01859741?term=Pinnacle&rank=7)

---

For further information and/or to refer a patient, please e-mail: Research@gacancer.com
**LUNG**  
1<sup>st</sup> line Stage IV Non-Squamous NSCLC  
**Location:** Network  
**NSH #:** C-246  
**Status:** ENROLLMENT ON HOLD  
**Protocol:** IMpower - A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination with Carboplatin or Cisplatin + Pemetrexed Compared with Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02657434?term=NCT02657434&rank=1](https://clinicaltrials.gov/ct2/show/NCT02657434?term=NCT02657434&rank=1)

**LYMPHOMA**  
1<sup>st</sup> line Hodgkin Lymphoma ≥ 60 years old  
**Location:** GCS Research Offices  
**NSH #:** C-093  
**Status:** ENROLLMENT ON HOLD  
**Protocol:** Seattle Genetics SGN 35-015 - A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above  
**Click for more information:** [https://www.clinicaltrials.gov/ct2/show/NCT01716806](https://www.clinicaltrials.gov/ct2/show/NCT01716806)

**MELANOMA**  
Unresectable Stage III or Metastatic Stage IV  
**Location:** Network  
**NSH #:** C-240  
**Status:** OPEN TO ACCRUAL  
**Protocol:** ECOG EA6141 Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma  
**Click for more information:** [https://www.clinicaltrials.gov/ct2/show/NCT02339571](https://www.clinicaltrials.gov/ct2/show/NCT02339571)

**MELANOMA**  
Stage III or IV Resected NED  
**Location:** Network  
**NSH #:** C-188  
**Status:** OPEN TO ACCRUAL  
**Protocol:** ELIOS TLPLDC Vaccine - A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02301611?term=elios+tlpldc&rank=1](https://clinicaltrials.gov/ct2/show/NCT02301611?term=elios+tlpldc&rank=1)

**MELANOMA**  
IIIa (N2a), IIIb, IIIc, or stage IV Resected  
**Location:** Network  
**NSH #:** C-248  
**Status:** OPEN TO ACCRUAL  
**Protocol:** SWOG 1404 - A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT02506153?term=s1404&rank=1](https://clinicaltrials.gov/ct2/show/NCT02506153?term=s1404&rank=1)

**MYELOMA**  
1<sup>st</sup> line Multiple Myeloma  
**Location:** Network  
**NSH #:** C-195  
**Status:** OPEN TO ACCRUAL  
**Protocol:** ECOG E1A11 Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma  
**Click for more information:** [https://clinicaltrials.gov/ct2/show/NCT01863550?term=e1a11&rank=1](https://clinicaltrials.gov/ct2/show/NCT01863550?term=e1a11&rank=1)

For further information and/or to refer a patient, please e-mail: Research@gacancer.com  
List Updated: 5/13/2016
## PROSTATE

<table>
<thead>
<tr>
<th>Location</th>
<th>NSH #</th>
<th>Status</th>
<th>Protocol</th>
<th>Click for more information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Network</td>
<td>NSH1089</td>
<td>OPEN TO ACCRUAL</td>
<td><strong>Prototype: Alliance A031201 - Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer</strong></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01949337?term=a031201&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT01949337?term=a031201&amp;rank=1</a></td>
</tr>
</tbody>
</table>

## SARCOMA

### UTERINE LEIOMYOSARCOMA

<table>
<thead>
<tr>
<th>Location</th>
<th>NSH #</th>
<th>Status</th>
<th>Protocol</th>
<th>Click for more information</th>
</tr>
</thead>
</table>

### SOFT TISSUE ADVANCED UNELECTABLE OR METASTATIC

<table>
<thead>
<tr>
<th>Location</th>
<th>NSH #</th>
<th>Status</th>
<th>Protocol</th>
<th>Click for more information</th>
</tr>
</thead>
</table>

### MYXOID LIPOMASARCOMA

<table>
<thead>
<tr>
<th>Location</th>
<th>NSH #</th>
<th>Status</th>
<th>Protocol</th>
<th>Click for more information</th>
</tr>
</thead>
</table>

## SOLID TUMOR

### SOLID TUMOR & LYMPHOMA

<table>
<thead>
<tr>
<th>Location</th>
<th>NSH #</th>
<th>Status</th>
<th>Protocol</th>
<th>Click for more information</th>
</tr>
</thead>
</table>

## PHASE I

### TGA - SOLID TUMOR

<table>
<thead>
<tr>
<th>Location</th>
<th>NSH #</th>
<th>Status</th>
<th>Protocol</th>
<th>Click for more information</th>
</tr>
</thead>
</table>

For further information and/or to refer a patient, please e-mail: Research@gacancer.com

List Updated: 5/13/2016
<table>
<thead>
<tr>
<th>PHASE I</th>
<th>Protocol: G1T28-03 - Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extensive Stage SCLC</td>
<td>Click for more information: <a href="https://clinicaltrials.gov/ct2/show/NCT02514447?term=g1T28-03&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT02514447?term=g1T28-03&amp;rank=1</a></td>
</tr>
<tr>
<td>Location: GCS Centerpointe</td>
<td></td>
</tr>
<tr>
<td>NSH #: C-233</td>
<td></td>
</tr>
<tr>
<td>Status: OPEN TO ACCRUAL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PHASE I</th>
<th>Protocol: A Multi-center Phase I/IIb Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location: GCS Centerpointe</td>
<td></td>
</tr>
<tr>
<td>NSH #: NSH1115</td>
<td></td>
</tr>
<tr>
<td>Status: OPEN TO ACCRUAL</td>
<td></td>
</tr>
</tbody>
</table>